Clinical studies have revealed that a high serum expression level of IL-6 in patients is associated with advanced tumor stages in various cancers (multiple myeloma, non-small cell lung carcinoma, colorectal cancer, renal cell carcinoma, prostate cancer, breast cancer and ovarian cancer) [29–32]. Here, IL6 is linked to plasma cell myeloma.